SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of SGT-003’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for SGT-003 is expected to reach an annual total of $185 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SGT-003 Overview
SGT-003 is under development for the treatment of Duchenne muscular dystrophy (DMD). It is administered through intravenous route. It comprises of adeno associated virus delivering nNOS-containing microdystrophin.
Solid Biosciences Overview
Solid Biosciences is a life sciences company that primarily focuses on the development of gene therapy candidates. The company’s main activities focus on diverse portfolio of gene therapies for the treatment of rare neuromuscular and cardiac diseases. Its product pipeline include SGT-003 for duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy, among others. Solid Biosciences‘ product pipeline is used for treating devastating diseases. The company operates in the biotechnology and healthcare sectors. It has operations across the US. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$104.3 million in FY2023, compared to an operating loss of US$88.2 million in FY2022. The net loss of the company was US$96 million in FY2023, compared to a net loss of US$86 million in FY2022.
For a complete picture of SGT-003’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.